title: Influence of inhibitors of eicosanoid metabolism on proliferation of rat hepatoma cells and on tumor-host interaction.
abstract: The influence of eicosanoids on the proliferation of hepatoma (HTC) cells was studied in culture and in tumor-bearing rats. The cells in culture demonstrated a capacity to metabolize arachidonic acid to eicosanoids including thomboxane B2 and the prostaglandins E2 and F2 alpha a. An effect of these eicosanoids on cell proliferation was suggested by the decreased cell division seen with an inhibitor of cyclooxygenase, flurbiprofen. A biphasic effect on the proliferation of HTC cells was observed with increasing concentrations of prostaglandin F2 alpha. These studies were extended to tumor-bearing rats where inhibitory effects on the early stages of tumor growth were seen with flurbiprofen. Bleeding times were decreased in tumor-bearing rats but were restored to control values by treatment with flurbiprofen and an inhibitor of thromboxane synthetase, OKY 046. These drugs and a thromboxane/endoperoxide receptor antagonist, SQ 29, 548, were not observed to have statistically significant effects on isotope-labeled water distribution but they had substantial effects on the maintenance of body weight by tumor-bearing rats. The data suggested that the cachexia of tumor-bearing animals may be mediated at least in part by the action of eicosanoids.
authors.affiliation: Department of Biochemistry, UMDNJ-New Jersey Medical School, Newark 07103.
authors.forename: J A
authors.initials: JA
authors.lastname: Cyran
authors.forename: T W
authors.initials: TW
authors.lastname: Lysz
authors.forename: M A
authors.initials: MA
authors.lastname: Lea
mesh_terms: D000179:Acrylates / Q000494:pharmacology*; D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism / Q000494:pharmacology; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002455:Cell Division / Q000187:drug effects; D002855:Chromatography, Thin Layer; D016861:Cyclooxygenase Inhibitors; D015237:Dinoprost / Q000378:metabolism / Q000494:pharmacology; D015232:Dinoprostone / Q000378:metabolism; D015777:Eicosanoids / Q000378:metabolism*; D005231:Fatty Acids, Unsaturated; D005480:Flurbiprofen / Q000494:pharmacology*; D006834:Hydrazines / Q000494:pharmacology*; D008114:Liver Neoplasms, Experimental / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008689:Methacrylates / Q000494:pharmacology*; D051381:Rats; D013929:Thromboxane B2 / Q000378:metabolism; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D014407:Tumor Cells, Cultured
chemical_list: D000179:Acrylates; D001095:Arachidonic Acids; D019086:Bridged Bicyclo Compounds, Heterocyclic; D016861:Cyclooxygenase Inhibitors; D015777:Eicosanoids; D005231:Fatty Acids, Unsaturated; D006834:Hydrazines; D008689:Methacrylates; D016718:Arachidonic Acid; D013929:Thromboxane B2; D005480:Flurbiprofen; C045749:SQ 29548; D015237:Dinoprost; D013930:Thromboxane-A Synthase; D015232:Dinoprostone; C034364:ozagrel